Mohs surgery plus short radiation for head and neck skin cancer
Part of Cancer clinical trials.
This trial studies a combination of Mohs surgery and a short course of radiation therapy for people with squamous cell skin cancer of the head and neck. The goal is to see if this approach is effective with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of skin cancer called squamous cell carcinoma on your head or neck, confirmed by biopsy.
- You have had Mohs surgery (with or without additional surgery) to remove the cancer within the last 70 days.
- Your cancer is stage T1 to T3 and has not spread to lymph nodes or other organs.
- You have had a CT or MRI scan of your head and neck, and a neck ultrasound, within the past 60 days.
- Your cancer falls into a high-risk or moderate-risk group based on factors like size, nerve involvement, or recurrence.
- You are not pregnant, not nursing, and have no serious medical conditions that would make treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two strategies after surgery for a type of skin cancer (cutaneous squamous cell carcinoma) that has a high chance of coming back. One strategy gives radiation therapy to the area, while the other just watches and checks for any signs of recurrence. The goal is to see if radiation can prevent the cancer from returning.
This trial tests a focused radiation treatment after surgery for people with a common skin cancer (squamous cell carcinoma) that has spread to the lymph nodes in the neck or near the ear. The goal is to see if this approach can prevent the cancer from coming back.
This trial looks at whether patients with head and neck squamous cell carcinoma who had a good response to chemotherapy and immunotherapy before surgery can safely have less radiation after surgery. It aims to reduce side effects while keeping treatment effective.
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a safer radiation plan that may reduce dose to the opposite (other) side of the neck while still treating the cancer spread risk. It uses special mapping to guide treatment and looks at patients whose cancer is already in an involved lymph node on one side.
Hear when a new Cutaneous Squamous Cell Carcinoma (CSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.